Please ensure Javascript is enabled for purposes of website accessibility
CORRESP

APELLIS PHARMACEUTICALS, INC.

6400 Westwind Way, Suite A

Crestwood, KY 40014

April 16, 2018

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re: Apellis Pharmaceuticals, Inc.
  Registration Statement on Form S-1
  File No. 333-224303
  Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Apellis Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-224303), as amended (the “Registration Statement”), so that it may become effective at 5:05 p.m. Eastern time on April 18, 2018, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.

* * * *


Very truly yours,
APELLIS PHARMACEUTICALS, INC.
By:  

/s/ David Watson

Name:   David Watson
Title:   General Counsel

 

cc: Cedric Francois, Apellis Pharmaceuticals, Inc.
  Stuart M. Falber, Wilmer Cutler Pickering Hale and Dorr LLP
  Brent B. Siler, Cooley LLP
   Darren DeStefano, Cooley LLP
   Divakar Gupta, Cooley LLP